Literature DB >> 523358

Pharmacokinetics of amphotericin B and flucytosine.

A Polak.   

Abstract

The absorption of flucytosine from the digestive tract is very good but minimal with amphotericin B. For this reason, amphotericin B has to be injected intravenously. Fungistatic levels are achieved rapidly with flucytosine and slowly with amphotericin B, since the dose has to be increased slowly. Distribution of flucytosine in other body fluids is high, whereas with amphotericin B it is poor. Flucytosine is excreted mainly via the kidney without metabolism, whereas amphotericin B is eliminated mainly by metabolism. Therefore, amphotericin B dosage does not have to be adapted to kidney function, which is the case for flucytosine. The half-life of flucytosine is short (hours), that of amphotericin B is long (days); flucytosine is haemodialysable, whereas amphotericin B, probably owing to the high protein binding, is not.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 523358      PMCID: PMC2425673          DOI: 10.1136/pgmj.55.647.667

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

1.  The kinetics of 5-fluorocytosine elimination in man.

Authors:  D N Wade; G Sudlow
Journal:  Aust N Z J Med       Date:  1972-05

2.  Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function.

Authors:  J Schönebeck; A Polak; M Fernex; H J Scholer
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

3.  5-Fluorocytosine in the treatment of candidiasis with acute renal insufficiency: its kinetics during haemodialysis and peritoneal dialysis.

Authors:  E Drouhet; P Babinet; J P Chapusot; D Kleinknecht
Journal:  Biomedicine       Date:  1973-09-20

4.  [Treatment of cryptococcal meningoencephalitis; value of 5-fluorocytosine].

Authors:  J J Dufresne
Journal:  Rev Med Suisse Romande       Date:  1972-08

5.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

6.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

7.  Use of 5-fluorocytosine in patients with impaired renal function.

Authors:  J K Dawborn; M D Page; D J Schiavone
Journal:  Br Med J       Date:  1973-11-17

8.  Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta.

Authors:  F A Jagdis; P D Hoeprich; R M Lawrence; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

9.  Bone marrow toxicity associated with 5-fluorocytosine therapy.

Authors:  C A Kauffman; P T Frame
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

10.  In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata.

Authors:  S Normark; J Schönebeck
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

View more
  16 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation.

Authors:  Małgorzata Prażyńska; Eugenia Gospodarek
Journal:  Mycopathologia       Date:  2014-01-17       Impact factor: 2.574

Review 3.  Antifungal agents in neonatal systemic candidiasis.

Authors:  J N van den Anker; N M van Popele; P J Sauer
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

4.  Quantitative extraction of amphotericin B from serum and its determination by high-pressure liquid chromatography.

Authors:  P R Bach
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

6.  Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin.

Authors:  S Rodenhuis; F Beaumont; H F Kauffman; H J Sluiter
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

7.  Aspergillus granuloma of the trigeminal ganglion.

Authors:  C M Wiles; R S Kocen; L Symon; F Scaravilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

Review 8.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 9.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Antibiotic levels in bronchial tree and in serum during selective digestive decontamination.

Authors:  H Gastinne; M Wolff; G Lachatre; R Boiteau; F P Savy
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.